Drug intelligence / Profile preview

carboplatin + paclitaxel

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

Carboplatin + paclitaxel is a combination chemotherapy regimen consisting of the taxane paclitaxel and the platinum-based agent carboplatin. In the context of the VULCANIZE-II trial led by The Netherlands Cancer Institute, this combination is being evaluated as neoadjuvant chemotherapy (NACT) followed by surgery for patients with locally advanced vulvar carcinoma (LAVC). Paclitaxel works by stabilizing microtubules, interfering with cell division, while carboplatin forms DNA adducts that inhibit replication and transcription, leading to apoptosis.

Brand names: TaxolParaplatin
Other names: Paclitaxel and CarboplatinCarbo/PaxNACT

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on carboplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + paclitaxel.

Explore the full profile